Curated News
By: NewsRamp Editorial Staff
September 09, 2026
Silo Pharma to Present PTSD Nasal Therapy Data at IPAC-RS Forum
TLDR
- Silo Pharma's SPC-15 stability data supports advancement, offering potential first-mover advantage in PTSD nasal treatment.
- SPC-15 met nine-month stability specs for assay, impurities, pH, microbiology; six-month accelerated data aligned with long-term.
- Silo Pharma's SPC-15 aims to improve PTSD treatment via nose-to-brain delivery, potentially enhancing patient outcomes.
- Silo Pharma will discuss its PTSD nasal therapy at the IPAC-RS 2026 Nasal Innovation Forum in Jersey City.
Impact - Why it Matters
This news matters because it signals tangible progress in the development of SPC-15, a potential new treatment for PTSD that leverages a nose-to-brain delivery method, which could offer faster onset and fewer side effects than current options. For patients suffering from PTSD, a condition with limited effective treatments, this could mean a new, more accessible therapy. For investors, Silo's stability data and forum participation are positive indicators of the company's scientific rigor and market potential, especially as it diversifies into cryptocurrency. The forum also provides networking opportunities that could lead to partnerships and accelerate clinical development, potentially bringing this innovative treatment closer to market.
Summary
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is set to showcase its innovative nasal delivery technology at the IPAC-RS 2026 Nasal Innovation Forum in Jersey City this September. CEO Eric Weisblum emphasized the importance of engaging with nasal drug development experts as the company advances SPC-15, a novel nose-to-brain therapy for PTSD. The announcement highlights promising preclinical data: the SPC-15 formulation and device met specifications for assay, impurities, pH, and microbiological quality over nine months, with six-month accelerated stability data consistent with long-term results. This progress underscores Silo's commitment to addressing underserved conditions like stress-induced psychiatric disorders and chronic pain.
Beyond its therapeutic pipeline, Silo Pharma is diversifying into cryptocurrency treasury, reflecting a growing trend among biotech firms. Its portfolio includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets for Alzheimer's and multiple sclerosis, developed in collaboration with leading universities. The company's participation in the forum signals a strategic push to establish SPC-15 as a viable treatment option, potentially offering a faster-acting and more targeted alternative to existing PTSD therapies. For more details, visit the full press release at https://ibn.fm/Dy4qf.
MissionIR, a communications platform that amplifies visibility for public companies, distributed this news. As part of the Dynamic Brand Portfolio under IBN, MissionIR leverages extensive syndication to reach investors and media. Silo Pharma's involvement in this forum and its robust data could attract investor attention, especially given the growing interest in psychedelic-inspired treatments and non-invasive delivery methods. The company's presence at such a specialized event underscores its dedication to innovation in CNS drug delivery.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma to Present PTSD Nasal Therapy Data at IPAC-RS Forum
